| Literature DB >> 30528419 |
Arrigo Francesco Giuseppe Cicero1, Federica Fogacci2, Marilisa Bove2, Marina Giovannini2, Maddalena Veronesi2, Claudio Borghi2.
Abstract
Hypercholesterolemia represents one of the main reversible cardiovascular risk factors. In this pilot clinical trial, we have tested the short-term efficacy and safety of a new combined cholesterol-lowering nutraceutical containing artichoke dry extract and berberine at enhanced bioavailability in subjects with moderate polygenic hypercholesterolemia in primary prevention for cardiovascular disease. After 2 months of treatment, the tested nutraceutical induced a significant reduction in plasma total cholesterol (-19%), low-density lipoprotein cholesterol (-16%), non-high-density lipoprotein cholesterol (-19%) and triglyceride levels (-15%), in association with a standardized control diet. No side effect has been observed during the trial. In conclusion, on the short-term, the tested nutraceutical has been shown to be well tolerated and effective, even if not containing any statin-like compound.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30528419 DOI: 10.1016/j.amjcard.2018.11.018
Source DB: PubMed Journal: Am J Cardiol ISSN: 0002-9149 Impact factor: 2.778